Podcasts about opra

Ramona Galey is an award-winning author and founder of the Alignment Circle. As a vibrational mentor and channel for Opra, Ramona empowers coaches, consultants, healers, and teachers to break through imposter syndrome and embrace their true potential. Her book is called, From Lonely to Fearless.https://www.ramonagaley.com/private-podcast

Ramona Galey is an award-winning author, vibrational mentor, and founder of The Alignment Circle, a transformative trance-coaching program that helps experts, coaches, and leaders overcome self-doubt, stress, and imposter syndrome ---- Find a Virtual Assistant at va.world -- Upgrade Your Brain    Unleash & Use Your Uniqueness   https://braingym.fitness/⁠  ---   Speaking Podcast/ Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   https://partnerco.world/   My Website https://partner.co/?custid=N6543249    ------------------    About my Guest Ramona Galey : Ramona Galey is an award-winning author, vibrational mentor, and founder of The Alignment Circle, a transformative trance-coaching program that helps experts, coaches, and leaders overcome self-doubt, stress, and imposter syndrome. Inspired by insights from Divine Intelligence Opra, Ramona developed the Clarity Activation Framework with the tagline, "Think Less, Thrive More." Her unique method empowers clients to shift from overthinking to heartfelt action, building resilience and reconnecting with their inner truth. Ramona's work provides practical, twice-weekly guidance for those seeking real results and a fulfilling life of presence and purpose. You can hear her insights on top podcasts like LOA Today and ZenCommuter, and find her book, From Lonely to Fearless, on Amazon. What we Discussed:   - Ramona's Change in her Journey (2 mins) - What is a Vibrational Mentor (5:45 mins) - What is OPRA (8:45 mins) - How to Stop the Mental Clutter (11 mins) - Kinesthetic processors (13 mins) - Moving Meditation (15:45 mins) - What feels good right Now (19 mins) - Find your own Guidance (23 mins) - Find a Meditation that works (24:45 mins) - Procrastinations (26 mins) - Her Book 'Lonely to Fearless' (33 mins) - Is this serving me or damaging me (38 mins) How to Contact Ramona Galey:   https://www.ramonagaley.com/ YouTube: http://bit.ly/3519lnl LinkedIn: https://www.linkedin.com/in/ramonagaley Facebook Group: https://www.facebook.com/groups/diyhappiness Facebook Personal Page: https://www.facebook.com/RamonaGaleyAndOpra Facebook Biz Page: https://www.facebook.com/profile.php?id=61558810310906 Facebook Author's Page: https://www.facebook.com/RamonaGaleyVibesMentorAuthor/  ---   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    http://meditationpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/meditationpodcast.org   Find a Virtual Assistant at va.world

In a world where experts often feel like frauds, Ramona Galey's journey to self-acceptance resonates deeply. After years of grappling with her own feelings of inadequacy—despite a rich tapestry of experiences as a classical musician, systems analyst, stockbroker, and nonprofit leader—she faced her greatest challenge: the profound loss of her life partner after 24 years. This pivotal moment sent her spiraling into self-doubt, questioning her worth and purpose. However, in the depths of her despair, Ramona discovered a transformative path. Guided by the teachings of Abraham Hicks, she began to embrace the spiritual principles of alignment and vibrational focus. This awakening revealed the importance of self-love and acceptance, leading her to understand that true success stems from within. Through her own healing journey, Ramona learned that the key to overcoming imposter syndrome is to acknowledge and celebrate one's unique gifts and experiences. As she embraced her true self, abundance began to flow effortlessly into her life, and her passion for mentoring others ignited. Today, as a vibrational mentor and channel for Opra, Ramona dedicates her life to helping coaches, consultants, healers, and teachers break free from the chains of self-doubt. She guides her clients to know and like themselves better, fostering improved interpersonal relationships and a greater ability to enjoy their work and lives. Through her signature programs, Ramona empowers experts to recognize their inherent worth, transforming their fears into confidence and their doubts into joy. In a safe, supportive environment, she helps them unlock their potential and step into their purpose, ensuring they know they are not alone on this journey. Join Ramona on the path to self-acceptance and fulfillment, where the promise of easy abundance and vibrant enjoyment of life awaits.    https://www.ramonagaley.com/private-podcast

Ramona Galey started one day, ten years ago, in the depths of despair and, before that day was done, was introduced to a path to her current life where she lives in joy and alignment and authenticity. You'll understand more when she explains Authenticity and self-love How to disrobe from the “brules” – the bullshit rules we grew up with personal assets, success, and entanglements blissipline “Pitfalls at The Peak” Ramona also introduces us to and explains Opra; she describes herself as a “Vibrational Mentor” and then tells why she came up with that term. Listen now and then go share this episode! Find Ramona at https://www.ramonagaley.com/ Learn more about Ramona and find all her links at https://boomwithabang.com/the-boomer-womans-podcast-ramona-galey/ https://buymeacoffee.com/agnesk https://agnesknowles.substack.com/  

Når vi har trang til at råbe op omkring noget, er det ofte fordi der gemmer sig en sorg eller et sår nedenunder. Kun hvis vi tillader dette opråb at komme ud, kan vi se og prøve at forstå hvad det er som ligger under. Jeg fortæller om min egen sorg over vores brudte slægtslinjer. At vi ikke, som andre indfødte folk, har fået vores folks magiske traditioner og skikke overrakt direkte af praktiserende ældre i vores landsby. Jeg mærker sorgen over det som overgik disse vise forfædre og mødre. Hekseforfølgelser, afbrændinger, tortur, udryddelser mm. Jeg fortæller om den mulighed jeg ser vi har, for at tage tråden op og fortsætte vævningen af det nordiske magiske tæppe. Ved at gå direkte til kilderne, træerne, bakker, sten, krage, rådyr etc... Det som er her, i vores nordiske landskab. Hvis vi går til dem, med lyttende, ydmygt hjerte, kan vi igen træde ind i ret relation med naturens kraft. Jeg nævner i dette afsnit Lyla June som er indfødt musiker og samfundsarrangør fra Turtle Island. Læs mere om hendes arbejde her: https://www.lylajune.com/ Susanne Schmidt KRAFTKVINDEN.DK

Dipl. Psych. Stephanie Cuff-Schöttle arbeitete von 2016-2019 als Diplom-Psychologin bei OPRA. Heute arbeitet sie als Diplom-Psychologin, Heilpraktikerin für Psychotherapie, systemische Familiensozialtherapeutin, integrative Paartherapeutin und Stressmanagementtrainerin rund um die Themen Identitäts- und Persönlichkeitsentwicklung, (Herkunfts-)Familie &/ oder Partnerschaft, Umgang mit rassismusinduzierten Stress und bei anderen persönlichen Themen, auch als Referentin. Zusammen mit Alina Hodzode hat sie im Jahr 2018 www.myurbanology.de gelauncht, eine Onlineplattform welche Schwarzes Leben in Deutschland sichtbar macht und BiPoC Perspektiven, Ressourcen, Expert*innen, Vernetzungs- und Jobangebote zur Verfügung stellt. Seit 2022 ist sie Mitgründerin der DE-CONSTRUCT Akademie, einer online Weiterbildungsplattform für Rassismus Sensibilisierung psychoszialer Fachkräfte. Ilja Gold (er) studierte Politik- und Erziehungswissenschaft sowie Organisationsentwicklung. Er arbeitet freiberuflich als Systemischer Berater (DGSF) und Supervisor sowie als Lehrbeauftragter an der Universität zu Köln. Im NS-Dokumentationszentrum der Stadt Köln ist er als wiss. Mitarbeiter tätig. Im Kontext systemischer Praxis und Weiterbildung bietet er aus einer als weiß gelesenen Perspektive mit familiärer Migrationsbiographie Workshops zu Macht-, Diskriminierungs- und Rassismuskritik an und begleitet Teams und Einrichtungen.

Send us a text and let us know what you think!We caught Shelby Stone fresh off the release her single "How Much More" and just before another, "Easy Tiger" and talked about how she got pulled into music in an unusual way and has continued down the path at a much faster rate than she anticipated.Find Shelby's tour dates, merch and more info at https://www.theshelbystone.com/If you love what we're doing here at Texas Toast, please support us by giving a 5-star review on Apple Podcasts and Spotify (and writing a quick review if you have the time), subscribing on YouTube and MOST IMPORTANTLY, sharing the show with a friend or family member! All of this helps us so much more than you know!Huge thanks to our friends at CH Lonestar Promo, Release Rocket & More Than Music Creations for supporting the show! Find all of our podcast episodes in audio or video format at www.texastoastpodcast.com! Support the Show.

Kolikokrat ste o kom, ki je delaven, slišali reči: “Priden je kot čebela,” nikoli pa niste slišali: “Marljiv je kot čmrlj?” Tako je morda zato, ker v ljudskem izročilu velja, da so čmrlji leni in počasni, čebele pa hitre in delavne. A kot lahko spoznamo na tokratni XKurziji, so čmrlji nenadomestljivi in še kako pomembni opraševalci. Ali ste vedeli, da so veliko hitrejši in spretnejši kot medonosna čebela? Da so sposobni opraševati tudi v vetru, dežju in mrazu in da je danes evropska trgovina s čmrlji vredna 50 milijonov evrov? Če smo vzbudili vašo radovednost, vabljeni z nami na obisk laboratorija za čmrlje na Nacionalnem inštitutu za biologijo v Ljubljani. Naš sogovornik je poznavalec in ljubitelj čmrljev dr. Danilo Bevk.

Dr. Sepideh Gholami and Dr. Aaron Scott join us to discuss the latest evidence-based guideline from ASCO on the management of locally advanced rectal cancer. They review the recommendation highlights on topics including assessment, total neoadjuvant therapy, timing of chemotherapy, nonoperative management, and immunotherapy. Additionally, we discuss the importance of this guideline for both clinicians and patients, and the outstanding research questions in the management of locally advanced rectal cancer. Read the full guideline, “Management of Locally Advanced Rectail Cancer: ASCO Guideline” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT  This guideline, clinical tools, and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.01160    Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at ASCO.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Aaron Scott from the University of Arizona Cancer Center and Dr. Sepideh Gholami from Northwell Health, co-chairs on, “Management of Locally Advanced Rectal Cancer: ASCO Guideline.” Thank you for being here, Dr. Scott and Dr. Gholami. Dr. Sepideh Gholami: Thank you for having us. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Scott and Dr. Gholami, who have joined us here today, are available online with a publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to kick us off on the content of this episode, Dr. Gholami, first, what is the purpose and scope of this guideline on locally advanced rectal cancer? Dr. Sepideh Gholami: Well, I think, historically, this is the group of patients with locally advanced rectal cancer for which we've used multiple therapies to address their management. And with the advent of the total neoadjuvant approach, we really have seen tremendous changes. So the purpose really of these guidelines was to consolidate the various approaches that we've had in several clinical trials and to provide the oncology community a general management recommendation guideline to really optimize the outcomes for these patients. And I would further notice that with the specifics to like which patients are included for these, so we define patients with locally advanced rectal cancer as any of those patients with T3 or T4 tumors and/or lymph node positive disease. Brittany Harvey: Great. I appreciate you providing that background and context of this guideline. So then, next, I'd like to review the key recommendations of this guideline. So, Dr. Scott, starting with the first section of the guideline, what are the recommendations for assessment of locally advanced rectal cancer? Dr. Aaron Scott: Yeah, thank you. So really, we were charged with trying to answer, I think, several very important questions as it comes to the treatment of locally advanced rectal cancer. And the first step in doing so is to define the patient group. So, as far as the first section goes in the assessment, we were really charged with defining what locally advanced rectal cancer means. We think that this is best done with a high resolution pelvic MRI, dedicated rectal sequence prior to any treatment for risk assessment and proper staging, and the use of standardized synaptic MRI is recommended that includes relation of the primary tumor to the anal verge, sphincter complex, pelvic lymph nodes, the mesorectal fascia, otherwise known as the MRF, and includes assessment of the EMVI tumor deposits and lymph nodes. Brittany Harvey: I appreciate you reviewing those highlights for assessment of locally advanced rectal cancer. So following that, Dr. Gholami, what does the panel recommend regarding total neoadjuvant therapy and standard neoadjuvant chemotherapy for patients with proficient mismatch repair or microsatellite stable tumors? Dr. Sepideh Gholami: Yeah, thanks so much for that question, Brittany. I would say that the guidelines really provide a lot more details, but in general, the consensus was that TNT should be offered as really initial treatment for patients with low rectal locally advanced rectal cancers or those who have higher risk for local and distant metastases. Those risk factors included anyone with either T4 disease, extramural vascular invasion and/or tumor deposits identified on the MRI for any threatening of the mesorectal fascia or the intersphincteric plane. Brittany Harvey: Excellent. So then, Dr. Gholami just discussed who should be offered TNT. But Dr. Scott, what are the recommendations regarding timing of TNT? Dr. Aaron Scott: So the way I take this question, think about this question, is a lot of the work that we put toward defining whether chemoradiation plus consolidation versus induction chemotherapy is the right choice, and there are a lot of implications to consider in this situation. The panel recognizes that the decision to proceed with chemoradiation followed by chemo versus chemotherapy followed by chemoradiation often depends on logistics regarding the time to treatment start, concern for distant metastases, and desire for local control that may impact surgical decision making. When we look at the subgroup analysis for overall survival of patients treated with TNT, it doesn't seem to matter which approach you take. Either induction or consolidation doesn't seem to have an impact on overall survival. However, there are other outcomes that may be of importance. Based on the CAO/ARO/AIO-12 randomized phase II trial, both pathologic complete response rates and sphincter sparing surgery were numerically higher with consolidation chemo. That said, there was no difference in disease free survival. So if you have a patient that really wants to consider some sort of sphincter sparing surgery, or a patient has a highly symptomatic disease burden, etc., these are patients that we would recommend starting with chemoradiation followed by consolidation chemotherapy. Brittany Harvey: Understood. And so you have both mentioned radiation included in treatment regimens. So Dr. Gholami, what is recommended in the neoadjuvant setting? Short course radiation or long course chemoradiation? Dr. Sepideh Gholami: Yeah, we actually had a really long discussion about this, but I think in general the consensus was that if radiation is included in any patient's treatment plan, neoadjuvant long course chemoradiation is preferred over short course RT for patients with locally advanced rectal cancer. And really the recommendation was based on the long term results that we've seen from the RAPIDO phase 3 clinical trial, which showed a significant higher rate of five year local regional failure with a total neoadjuvant approach with short course of 10% compared to the standard chemo RT with only 6% of the local recurrence rate. So that's why they opted for the long course, if the patients can actually tolerate it. Brittany Harvey: Excellent. I appreciate reviewing the recommendation and the supporting evidence that the panel reviewed to come to those recommendations. Then following that, Dr. Scott, for those patients who have a complete clinical response after initial therapy, what is recommended regarding nonoperative management? Dr. Aaron Scott: First, I would like to just say that this is really an area that still remains somewhat controversial and needs more investigation to best select patients for this approach. This topic was not systematically reviewed for the ASCO guideline. However, the expert panel was surveyed and most agreed with the time interval used in the OPRA phase 2 trial, which assessed patients for clinical complete response within eight weeks plus or minus four weeks after completion of TNT. Expert panel members and reviewers noted that if the radiation therapy component of TNT is delivered first, then an eight week interval following subsequent chemotherapy may result in a prolonged period of no treatment and therefore a first assessment of this response in this scenario would occur on the earlier side of the recommended interval. If a near clinical complete response is noted, then reevaluation within eight weeks is recommended to assess for developing a clinical complete response. Brittany Harvey: Absolutely. That information is helpful to understand what is recommended regarding nonoperative management and clinical complete responses. Then the final clinical question, Dr. Gholami, for patients with tumors that are microsatellite instability high or mismatch repair deficient, which treatment strategy is recommended? Dr. Sepideh Gholami: Yeah, I think we really came up to summarize that in general, when there is no contraindication to immunotherapy, then patients with MSI high tumors should be really offered immunotherapy. The evidence for this recommendation was relatively low, though, just due to the small sample size of the data that's currently available. But we did want to highlight that the data is very promising, but a definitive recommendation by the committee should be validated in future larger clinical trials. Brittany Harvey: Absolutely. Well, thank you both for reviewing the highlights of these recommendations for each clinical question. Moving on, Dr. Scott, in your view, what is the importance of this guideline and how will it impact both clinicians and patients with locally advanced rectal cancer? Dr. Aaron Scott: This would be the first guideline through ASCO to spell out management options for locally advanced rectal cancer. This has largely been needed due to the increased number of phase II and III trials investigating the specific patient population that have investigated a variety of different TNT approaches and treatment combinations utilizing systemic therapy, radiation, and surgical treatment. So, in this guideline, we really set out to define what locally advanced rectal cancer is, have organized and analyzed impactful large randomized studies to address multimodality therapy, and have consolidated this information into what we consider a concise and generalizable approach to help clinicians and patients individualize their management based on specific clinical pathologic features of their cancer. Brittany Harvey: Yes, this has been a mountain of work to review all the evidence, consolidate it into a concise review of that evidence, and develop recommendations for best clinical practice for management of locally advanced rectal cancer. So then, finally, to wrap us up, Dr. Gholami, what are the outstanding questions regarding management of locally advanced rectal cancer? Dr. Sepideh Gholami: Yeah, I think I just want to reiterate, Brittany, what you mentioned, this was a tremendous amount of body work, and we really would like to thank the committee and everyone from ASCO to help us with creating these general guidelines. I think one of the outstanding questions really still remains is the use of circulating tumor DNA as a management tool for patients with rectal, locally advanced rectal cancer. And also, I think outside of what we can think of the straightforward populations to deduce from PROSPECT, be really interested to see what other patient populations, for example, could also potentially maybe avoid radiation therapy. And lastly, I think we really wanted to highlight that this guideline really focuses on the locally advanced, and it would be great to see future guidelines for early stage rectal cancer which will be forthcoming. Brittany Harvey: Definitely. We'll look forward to answering those outstanding questions and for upcoming guidelines on earlier stage rectal cancer. So, I want to thank you both so much for, as you said, the tremendous amount of work that went into these guidelines and thank you for taking the time to speak with me today, Dr. Scott and Dr. Gholami. Dr. Aaron Scott: Thank you. Dr. Sepideh Gholami: Thank you so much for having us. Appreciate it. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please read and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Čočka s ostružinami, pošírovanou hruškou, čerstvým kravským sýrem a semínky jde neuvěřitelně k sobě. Opražený sýr v tomto salátu chutná jako uzené. Lehký, rychlý a osvěžující letní nápad. A pochutnají si i ti, kteří by si normálně samotnou čočku nedali. V jedné z nejprostornějších kuchyní tvořila Dominika Moldaschlová ze Šťáhlav.

Zaspomíname si na klasika slovenského filmu - režiséra Vladimíra Bahnu, ktorý sa narodil pred 110 rokmi. A tiež na legendou opradeného kamaldulského mnícha Cypriána, ktorý žil v Červenom Kláštore v Pieninách na severe Slovenska a od narodenia ktorého uplynulo už 300 rokov.

V Sloveniji najbolje uspevajo v Istri in Goriških brdih, jih pa najdemo tudi drugje. Ker zelo dobro uspevajo na področju Mediterana, predstavljajo pomemben del mediteranske prehrane. Najbolje je, če jih uživamo sveže, priljubljene so tudi sušene ali v marmeladah in džemih. O figah bo govor v današnjem Torkovem kvizu, sogovornica bo prof. dr. Metka Hudina z Oddelka za agronomijo Biotehniške fakultete Univerze v Ljubljani.

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal contingent is the TNTCRT trial, looking at total neoadjuvant therapy vs concurrent chemoradiotherapy. While the world may have moved forward, this trial could provide further evidence of the path we should be taking.Links to studies discussed in this episode (subscription may be required)NEOPRISM-CRC: LinkTNTCRC: LinkNeoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labelled, phase Ib study: LinkFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Už je to 20 let, co vznikla Knihovna Václava Havla, která se stala výrazným kulturním místem v centru Prahy. Jak toho dosáhla, kam směřuje dál a čím své dvě dekády fungování oslaví, o tom jsme si povídali s jejím programovým ředitelem, spisovatelem Jáchymem Topolem a dramaturgyní Erikou Zlamalovou.Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Už je to 20 let, co vznikla Knihovna Václava Havla, která se stala výrazným kulturním místem v centru Prahy. Jak toho dosáhla, kam směřuje dál a čím své dvě dekády fungování oslaví, o tom jsme si povídali s jejím programovým ředitelem, spisovatelem Jáchymem Topolem a dramaturgyní Erikou Zlamalovou.

This week on Gun For Hire Radio... 2A Heavy Hitter Rich Ford joins us in the studio and Government Carpetbagger signs the Orwellian anti OPRA request bill, or the Non Freedom of Information Act. Guess what? The street communists that supported him are not happy. Welcome to our world. Tune in, like, follow, share. The post The Gun For Hire Radio Broadcast: Episode 681 appeared first on Best Gun Range NYC and NJ Area | Gun Range Near Me.

When I interviewed Victoria back in March, she was still single. Since that time, Victoria has met someone and says she is very much in love. She also knows she can change her mind at any given moment as she continues to follow her guidance and trust her intuition.Whether you're interested in dating or not, you'll get a lot out of today's discussion with Victoria-Monique Balmatie Jagroe. Victoria is a spiritual student and teacher, a YouTube personality, a Transformational coach, athlete and creator of a vegan lipstick.  In this interview, Victoria candidly shares her journey of overcoming a heart-wrenching breakup, her insights on using Neville Goddard's teachings, and her experiences in dating and self-love. We explore the importance of focusing on oneself, releasing resistance, and having fun in life and during the dating process. We also discuss practical tips for attracting a romantic partner and the importance of following one's intuition. I share a lot too, including my many years of navigating the dating arena as a single mom before marrying my husband 20 years ago. Connect with Victoria-Monique Balmatie Jagroehttps://www.youtube.com/@Victoria-Moniquehttps://moniquebjagroe.com/hello-freedom/https://www.instagram.com/victoria_moniquebjagroe/https://www.instagram.com/fralippolippieVictoria's YouTube video with Ramona Galey who channels Opra, “Where's My Dude? Advice on Attracting Your Perfect Partner”Victoria's YouTube video with Ramona Galey who channels Opra, “Love & Dating Made Easy! A Conversation with Ramona Galey on Dating and More”Support the Show.CONNECT WITH RHONDA RYDERFREE Guided Visualization on Abundance with Rhonda RyderIt includes six of my top episodes on prosperity. https://deliciousalignment.com/abundance/FREE Love Your Body Online Course 20+ Videos based on my five steps to loving your body and making peace with food.https://deliciousalignment.com/freecourse Delicious Alignment Facebook Grouphttps://www.facebook.com/groups/deliciousalignmentInstagram@deliciousalignmentThe BookDelicious Alignment: How 25 Women Learned to Love and Transform Their Bodies Using Abraham-Hicks and the Law of Attractionhttps://amzn.to/3fkTDoyPrivate Coaching with Rhondahttps://deliciousalignment.com/coaching/Websitehttps://deliciousalignment.comPodcast Advertising InquiriesContact us at support@deliciousalignment.comSupport the Showhttps://paypal.me/deliciousalignment

Vi kickstartar veckans poddavsnitt med besök av Orexos VD Nikolaj Sørensen. Bolagets kassako Zubsolv bekämpar opioiddrogberoende och parallellt utvecklar man nya läkemedel genom sin plattform AmorphOX. Nikolaj uppdaterar oss med sin syn på potentialen för Zubsolv, pågående rättegång och nästa marknadslansering. Vi följer upp detta med analytiker Ludvig Svensson som ger oss investeringscaset i Integrum. Familjen Brånemark är pionjärer inom titanimplantat och vi får höra mer om marknadspotentialen för Integrums produkt OPRA-systemet i USA och övriga marknader. Avslutningsvis ger Klas Palin investeringscaset i Initiator Pharma, ett kostnadseffektivt läkemedelsbolag som utvecklar preparat inom sexuell dysfunktion. Lyssna in!

V této epizodě Evropy zblízka se redakce zaměřila na probíhající kampaň do eurovoleb. Konkrétně na menší hráče – koalici Stačilo; SPD a Trikolory; Přísahy a Motoristů a SOCDEM a Budoucnosti. Kdo jsou jejich kandidáti a s jakým programem do voleb jdou?

The Oncology Journal Club - Delivering Oncology News DifferentlyThe Oncology Podcast, part of The Oncology Network, is proud to present Episode 3 in the second series of The Oncology Journal Club Podcast.Dr Kate Clarke explores a clinical conundrum with the latest insights on neo-adjuvant immunotherapy for DMMR, MSI-high GI cancers, discussed with the clarity and depth you've come to expect from our team. For Professor Craig Underhill's main paper segment, Dr. Ashray Gunjur drops by to discuss the microbiome's predictive power in immunotherapy responses, Professor Christopher Jackson delves into the OPRA study's latest findings on chemo-radiotherapy sequencing for rectal cancer, bringing to light the pivotal role of patient-centred discussions.In Quick Bites, the discussion hits home with the three S's—sitting, shitting, and sex—and their profound impact on post-cancer quality of life. Highlighting the importance of comprehensive support systems in these often-overlooked areas, we also dissect the worrying trend of early-onset colorectal cancer and its broader implications. With a review of a study about the duration of immunotherapy in non-small cell lung cancer, this episode promises to fuel ongoing debates on treatment duration and patient outcomes, highlighting our commitment to keeping you at the forefront of oncology discourse.The conversation takes a crucial turn as we tackle the uncomfortable yet necessary topic of presenting unfunded treatment options in oncology, exposing the delicate balance healthcare professionals must maintain in an era marked by scarce resources and rising demands.For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

Ramona Galey's transformative journey to channeling Opra (not Oprah Winfrey) has helped thousands of people tap into the true essence of their abundance in all areas of their lives including health, wealth, romance and happiness. As you listen to Opra, you will feel immense love, possibly better than you have ever felt love before. This helps you know what the love from your own Inner Being feels like, so you can experience it again and again.Here are the questions Opra answered in this episode:Concern about chronic digestion issuesHow to make the right medical decisions for her 7-year-old sonHow to get comfortable spending money on a car she really wantsWhen a psychic tells you something upsettingWhy do different channelers sometimes say different things?Is it necessary to find the emotional cause for an illness in order to get better?Connect with Ramona Galeyhttps://www.ramonagaley.com/Facebookhttps://www.facebook.com/RamonaGaleyAndOpraEpisode SponsorsGina Mallison's FREE GiftSeason 1 of the "Gina & Opra Sessions" (Opra is channeled by Ramona Galey)Go to https://www.mallisontv.com/love Once you get to the checkout screen, enter the word love in the coupon field to gain instant access to Season 1. ($88 value)Reid Thompson's FREE GiftReceive a FREE Guided Meditation from Reid when you pre-order his book, “The Unicorn Frequency.”How to get your Free Guided Meditation: “My Unicorn Magic” ($29.99 value)Pre-Order Reid's book here:https://amzn.to/491rMD2Next, dm a screen shot of your pre-order receipt to Redi via Instagram @reidonk and he will send you the meditation at no charge.Support the showCONNECT WITH RHONDA RYDERFREE Guided Visualization on Abundance with Rhonda RyderIt includes six of my top episodes on prosperity. https://deliciousalignment.com/abundance/FREE Love Your Body Online Course 20+ Videos based on my five steps to loving your body and making peace with food.https://deliciousalignment.com/freecourse Delicious Alignment Facebook Grouphttps://www.facebook.com/groups/deliciousalignmentInstagram@deliciousalignmentThe BookDelicious Alignment: How 25 Women Learned to Love and Transform Their Bodies Using Abraham-Hicks and the Law of Attractionhttps://amzn.to/3fkTDoyPrivate Coaching with Rhondahttps://deliciousalignment.com/coaching/Websitehttps://deliciousalignment.comPodcast Advertising InquiriesContact us at support@deliciousalignment.comSupport the Showhttps://paypal.me/deliciousalignment

Best-selling author and wellness advocate Kris joins me to talk health, cancer as a teacher, working with fear, listening to the body, “the wellness “industry”, who to listen to, inflammation, behavioural change, discipline, proportionality, what Opra's like, grief, griefphobia, the way out is through, life reptures and more. A lovely fun interesting one. More information about Kris Carr's work - https://kriscarr.com/   To join our courses and our community go to www.embodimentunlimited.com Find Mark Walsh on Instagram https://www.instagram.com/warkmalsh/

What if we told you that traumatic events can serve as catalysts for our spiritual ascension? This may sound abstract, but prepare to have your perspective altered as we spend an enlightening hour with Ramona Galey, a vibrational mentor whose journey from non-profit leadership to spiritual mentorship was sparked by a personal tragedy. Ramona will recount the transformative experience of her partner's death and how channeling Opra and infinite intelligence in a trance-like state has become a part of her spiritual practice.Ramona takes us on a deeper dive into the fascinating world of vibrations and manifestation. She explains how emotions carry specific vibrations and how we can navigate these emotional scales to attract more of what we desire in life. The conversation also uncovers the complexities of mixed vibrations and their impact on our manifestations. Get ready to learn some practical tips on how to elevate your vibrational state to catalyze personal growth.Finally, we explore Ramona's unique approach to personal development coaching, drawing from her life-changing experiences. She gives us a sneak peek into her private and group coaching methods, and how she helps others tap into their inner greatness.We also discuss her first book, Choosing Loneliness, in which she explores how embracing solitude can lead to self-love and a higher vibrational state. As we wrap up our time with Ramona, she extends a heartfelt invitation to you for a private conversation to help you embark on your spiritual journey. Prepare to have your heart stirred and your perspective broadened in this episode full of wisdom and insights.CALL TO ACTION: PRIVATE VIP INVITATION FOR LISTENERS: HTTPS://WWW.RAMONAGALEY.COM/PRIVATE-INVITATION  Support the showWe hope you found the episode to be enlightening and insightful. Our goal is to create content that not only entertains but also helps you grow spiritually and connect with your inner self. If you enjoyed listening to this episode, we would greatly appreciate it if you could take a moment to like, subscribe, and write a review. Your feedback is incredibly valuable to us and helps us to improve the quality of our content and reach a wider audience. We believe that by sharing knowledge and insights about spirituality, we can help to inspire positive change and personal growth. So, if you find our podcast to be meaningful and informative, we encourage you to share it with your friends and family. You TubeFacebookFacebook Group The Road To Spiritual AwakeningSpiritual Awakening 101 Guide

Opra Admi- Gurwinder Mann ਓਪਰਾ ਆਦਮੀ- ਗੁਰਵਿੰਦਰ ਮਾਨ The protagonists of the story, Kartara and Pali are both strangers to each other yet they are bound to meet at the behest of destiny. Kartara, who has been on a journey to some place, passes through a village. As the day ended Kartara found shelter at one of the most respectable families of that area. Pali was the daughter of the family and Kartara found her modest and kind. Somehow the situations turn in such a way that Pali and Kartara eloped, atleast this was the belief of the villagers but truth was not known to anyone. Why they did that? What really happened that led to such an act? These questions demand introspection while listening to this beautiful story... The cover art of this audiobook has been made by Artist Gurdish Pannu and Dr. Ruminder has given voice to this punjabi short story. ⁠⁠⁠⁠ #moralstory #trendingpodcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#video⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#village⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#lifemotivation⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #trendingshortstory ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#motivational⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #trendingaudiobooks #punjabishortstories ⁠#emotional⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#punjabistories⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#hardwork⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #punjabipodcast #famouspodcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#commitment⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #podcast #indian #india #emotionalstory ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#life⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#audiolibrary⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #audiobooks ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#story⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#audiobook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #punjabiaudiobooks ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#punjabi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#punjab⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #shortstories ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#punjabifolk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#listenaudiobooks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#books⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#lovers⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #artistgurdishpannu ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#lifestyle⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #drruminder ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#viral⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#videos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #trending #trendingonspotify

Check out this week's QuadCast as we highlight TNT with chemoradiation to reduce the need for surgery on the OPRA trial, the safety of a laparoscopic Whipple, the dangers of HER2-targeted agents during pregnancy, and more. QUADSHOT

@AviNMash @JoeySolitro @StockSavvyShay are back for Episode 96 after Avo Locks nailed $NFLX buy on last weeks episode (Joey props too for the Buy hat tip)  Underdog Pickem's - 1 minute who we like this week in the NFL  Recap and New Buy | Sell | Hold  Tesla | Align Technology |  TransMedics Group | Netflix  EARNINGS PREVIEW:  Meta | Microsoft | Spotify | Snapchat | Amazon  Monday: $CDNA, $LOGI, $CLF, $WHRTuesday: $KO, $VZ, $GE, $GM, $SPOT, $MSFT, $V, $SNAP, $TXN, $TDOCWednesday: $TMUS, $BA, $ADP, $CZOO, $META, $IBM, $NOW, $ALGN, $MAT, $QS, $PIThursday: $MA, $MRK, $CMCSA, $UPS, $LUV, $MBLY, $OPRA, $AMZN, $INTC, $CMG, $F, $ENPH, $LHX, $DXCMFriday: $XOM, $CVX, $ABBV, $SNY, $CHTR, $TROWCHECK OUT SPECIAL PROMOTIONS FOR OUR LISTENERS: Exclusive UNDERDOG FANTASY SPORTS Get up to Bonus Match instantly (Up to $500) and win up to $3M in their BestBall Mania + $15M In total Prizes.  Promo Code: PTT Signup Link: https://play.underdogfantasy.com/p-pounding-the-table Interested in Automated Trading Bots?  Peakbot is our favorite automated trading bots; great for non experts to leverage covered calls. PeakBot (www.UsePeakBot.com)Promo code: PTTWant to Contact Us?  Email us at Hosts@PoundingTheTablePodcast.comLegal Disclaimer:The thoughts and opinions expressed on this podcast, are solely for entertainment purposes and should not be construed as investment advice. The content provided is based on personal experiences, analysis, and general knowledge about stocks and the financial market.The information shared on this podcast is not intended to be a substitute for professional financial advice. Listeners should always consult with a qualified financial advisor or professional before making any investment decisions. Investing in stocks and other financial instruments carries inherent risks, and individuals should carefully consider their own financial situation, risk tolerance, and investment goals before engaging in any investment activities.The hosts and guests on this podcast are not licensed financial advisors or professionals. They are sharing their personal opinions and experiences, which may not be suitable for everyone. The accuracy, completeness, and timeliness of the information presented cannot be guaranteed, as the stock market and investment landscape are subject to constant changes.Any actions taken based on the content of this podcast are done at the listener's own risk. The podcast hosts, guests, and producers assume no responsibility or liability for any investment decisions, losses, or damages incurred as a result of the information provided on the podcast.

Glavni imam ABIC-a Deer Park u Melbourneu hafiz Halil Mehtić nakon dvogodišnje službe u Australiji vraća se za Bosnu i Hercegovinu. Ovaj penzionisani profesor sa Islamskog pedagoškog fakulteta Univerziteta u Zenici bio je vrlo aktivan tokom svoje imamske službe. Željeli smo saznati kako je proteklo vrijeme provedeno u BH zajednici u Melbourneu, kakve utiske nosi iz Australije i šta smatra vrijednim što je u ovom vremenu dao svojim džematlijama.

Today on the Podcast, I'm joined by the amazing Karen Lee, co-founder of LEZÉ the Label, a Recycled Workleasure brand that feels like Pajamas. Lee has been featured in Forbes, People and Opra. Karen has been on the podcast 2 other times so she's now officially a regular and you'll find out why when you tune int, Karen is extremely down to earth, funny and also shares her wisdom of how she's overcome some incredible struggles in her business including being almost 200 thousand dollars in debt. We also dive into topics like community, finances, getting clear on your purpose and so much more! Connect: Connect with LEZÉ: https://lezethelabel.com/ Follow LEZÉ on Instagram: @lezethelabel We are so excited to have Karen as one of our incredible speakers for our Power of Purpose Conference on August 25th! Join us for our in-person POWER OF PURPOSE CONFERENCE: businessbabescollective.com/events *We are now over 50% of our capacity Want to join us as a Vendor or Sponsor? Apply here:www.businessbabescollective.com/vendor-application Want to work with us behind the scenes? Apply to be a volunteer here: www.businessbabescollective.com/volunteer-application Get ready for an inspiring full-day conference featuring inspiring entrepreneurs and speakers sharing their raw perspectives on building purpose-driven businesses. You'll also have the opportunity to Connect with like-minded women, connect and shop local vendors, and enjoy an epic after-party to leave with your heart FULL and incredibly inspired! We also will have a group chat for those that want to connect before the event, just DM us your confirmation at @vancitybusinessbabes to be added! Connect with Danielle: Come hang out on Instagram: @danilivinglife and @businessbabesco Get Access to our Free Business Breakthrough Workshop: businessbabescollective.com/breakthrough Our Curated Resources for Small Business Owners: https://www.businessbabescollective.com/resources

U novoj epizodi podkasta govorimo o razlici iizmeđu opraštanja i opravdavanja ljudi u našem životu.Pitanja na koja odgovaram:Šta je opraštanje i šta ono pordrazumijeva?Šta je opravdavanje?Kako iz pravdanja doći do opraštanja?Ukoliko želite da pratite informacije o edukacijama, radionicama, kao i korisnim sadržajima, pridružite se zajednici na mojoj newsletter listi: https://martinadjokic.com/newsletterA možete me pronaći i na Instagramu: https://www.instagram.com/martina.djokic/

This is a conversation that took my breath away more than once (in the best possible way)! Today I get to share a recorded conversation that I had with Ramona Galey who Channels the Energy of Opra. The majority of the interview is between Ramona and I - and - Ramona brings Opra in for a very enlightening Q & A where I am the one asking the questions. Questions that I felt may be pertinent to many who consider themselves to be on a Conscious Path of Awakening at this time on Earth. I loved, loved, loved this interview, and as you'll hear... Ramona and I laughed a ton during this conversation -- the energy overall was giddy and empowering

AI Eye Podcast: AI Stocks discussed: (OTCPINK: $GTCH) (NasdaqGS: $OPRA)

AI Eye Podcast: AI Stocks discussed: (OTCPINK: $GTCH) (NasdaqGS: $OPRA)

Chef Tanya Holland's new cookbook – like her family – is rooted in the people and the food of the historical migration from the South to the West. Holland, legendary for her former West Oakland soul food restaurant Brown Sugar Kitchen, weaves recipes with stories of California's Black culinary pioneers and food industry entrepreneurs in her new cookbook, “California Soul: Recipes from a Culinary Journey West”. We talk with her about the stories that food holds and her California Soul. Guests: Tanya Holland, author, "California Soul" and "Brown Sugar Kitchen: New-Style, Down-Home Recipes from Sweet West Oakland;" host, "Tanya's Kitchen Table" on the Opra.

Posle samo sedam meseci, napokon smo dočekali vladu! Upravo o tome pričamo u 73. izdanju Njuz Podkasta i analiziramo ko su gubitnici, a ko dobitnici novog ovog sastava. Opraštamo se od Zoke i Vulina i pratimo herojski povratak Gašića i Dačića. SNS je proslavio 14. rođendan u Leskovcu, a mi smo ukapirali da već 9 godina pričamo o njima. Mnogo je. Čak je i Veliki čas u Kragujevcu ostao je u senci ovog događaja. Staša je debitovala u Skupštini. Nedostaje nam Langura. I susedstva iznenađujća reč - Pukao je Milo (u Podgorici). U Relax temi pričamo o novom nametu u kafićima - dodatku za grejalice i kako prevariti sistem koji te laže u ova smutna vremena.

Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg.   TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024   Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo

Dnes pro vás mám několik rad do kuchyně.

Podržite podcast jednokratnim donacijama:

Um cantinho e um violão / Este amor, uma cançãoPra fazer feliz a quem se amaMuita calma pra pensar / E ter tempo pra sonharDa janela vê-se o Corcovado / O Redentor que lindoQuero a vida sempre assim com você perto de mimAté o apagar da velha chamaE eu que era triste / Descrente deste mundoAo encontrar você eu conheci / O que é felicidade meu amor O Rio de Janeiro continua lindo... mas tá perigoso...

Jeter v. Sam's Club - “mode of operation” does not apply where the grapes are in closed containers versus open top bags; trail court not to handle motions in limine as dispositive motionsRivera v. Union County Prosecutor's Office - Common law right to demand Internal Affairs investigation report - redacted for confidentiality even when prohibited under OPRAState v. Anthony Sims, Jr. - Miranda process must include clear statement about charges - no need for police to predict other future charges; preliminary hearing testimony - witness subject to cross examination by defense - meets requirement for admission under the Confrontation ClauseCongrats to Bruce Greenberg - 2,000 Posts on the AppellateLaw-NJ.com BlogThe 2,000th Post on This Blog: The Anniversary of Campbell v. Department of Civil ServiceBy Bruce D. Greenberg on Apr 01, 2022 05:34 pmThe BOLD SIDEBAR 5-star Rating where you listen to Podcasts.Check out our sound engineer Nick Bates at: Bandcamp - https://nick-bates.bandcamp.com and Twitter - https://twitter.com/nickbatesmusic